CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1. 11. (Canceled)
- 12. (Previously presented) A method of treating neuralgia pain or neuropathic pain, in a mammal, including a human, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine or a therapeutically utilizable salt thereof with a sodium channel-inhibiting substance or a therapeutically utilizable salt thereof.
- 13. (Previously presented) The method of claim 12, wherein said sodium channel-inhibiting substance is selected from tolperisone, eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, and metixen, or pharmaceutically utilizable salts thereof.
- 14. (Previously presented) The method of claim 12, wherein said sodium channel-inhibiting substance is selected from tolperisone, eperisone, silperisone, and other tolperisone analogs, and pharmaceutically utilizable salts thereof.
- 15. (Previously presented) A method of treating neuralgia pain or neuropathic pain, in a mammal, including a human, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine with tolperisone, eperisone, silperisone, or another tolperisone analog, or a pharmaceutically utilizable salt thereof.
- 16. (Withdrawn) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said sodium channel-inhibiting or -influencing are administered separately or consecutively.
- 17. (Withdrawn) The method of claim 12, where said pains are associated with neuralgias.

Application No.: 10/727,655

- 18. (Withdrawn) The method of claim 12, where said pains are associated with arthritis and arthrosis.
- 19. (Withdrawn) The method of claim 12, where said pains are associated with chronic or episodic tension headache.
- 20. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower spastic paraparesis syndrome, disturbances of the spinal blood circulation, and cerebral paralysis involving lower spastic paresis).
- 21. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia ("Stuempel paraplegia").
- 22. (Withdrawn) The method of claim 12, where said pains are associated with tetraparesis in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.
 - 23. (Canceled)
- 24. (Previously presented) The method of claim 12, wherein said sodium channel-inhibiting substance or therapeutically utilizable salt thereof is administered simultaneously with retigabine.
- 25. (Previously presented) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said sodium channel-inhibiting substance are administered separately or consecutively.
- 26. (Previously presented) The method of claim 12, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.
- 27. (Previously presented) The method of claim 15, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.